Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | ACACA | Q13085 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5524976 | 1.00 | NPC1L1 (0.47) | NPC1L1ROCK2ROCK1NPC1HPGD | |
| SCHEMBL5527711 | 0.94 | NPC1L1 (0.47) | NPC1L1ROCK2ROCK1NPC1HPGD | |
| SCHEMBL5527710 | 0.94 | NPC1L1 (0.47) | NPC1L1ROCK2ROCK1NPC1HPGD | |
| SCHEMBL5525008 | 0.87 | ACACB (0.48) | NPC1L1ROCK2ROCK1ACACB | |
| SCHEMBL5525010 | 0.87 | ACACB (0.48) | NPC1L1ROCK2ROCK1ACACB | |
| SCHEMBL4553284 | 0.82 | ROCK2 (0.50) | NPC1L1ROCK2ROCK1 | |
| SCHEMBL5530244 | 0.80 | AR (0.46) | NPC1L1ROCK2ROCK1RAB9A | |
| SCHEMBL5530238 | 0.80 | AR (0.46) | NPC1L1ROCK2ROCK1RAB9A | |
| SCHEMBL5532506 | 0.79 | NPC1 (0.44) | NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL5532501 | 0.79 | NPC1 (0.44) | NPC1HPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | NPC1L1 2558/4885ROCK2 4012/4885ROCK1 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.